INTRODUCTION: Vacuum erection devices (VEDs) have been approved in the United States since 1982 and offer a viable alternative to oral phosphodiesterase type 5 inhibitors (PDE5i), injections and transurethral suppositories.
Studies have demonstrated efficacy in erectile dysfunction (ED) associated with a variety of conditions. More recently, this modality has been evaluated in initial phosphodiesterase inhibitor nonresponders as well as for post-prostatectomy penile rehabilitation. AIM:This article provides a detailed overview of the history of VEDs, a review of the literature, and a concise description of their new applications in modern urological practice.
METHODS: A retrospective review of publications relevant to the field of VEDs.
MAIN OUTCOME MEASURES: Review of the historical milestones, evolution, and modern utilization of VEDs in modern urological protocols.
RESULTS: Studies have demonstrated efficacy in ED associated with a variety of conditions. Early penile rehabilitation after surgery for prostate cancer with the VED appears to improve erectile function and penile length. Adverse events are transient and not serious.
CONCLUSIONS: The VED has continued to show efficacy for treatment of ED due to various etiologies and should be considered an attractive second-line therapy. In select cases such post-prostatectomy penile rehabilitation, as well as in men who cannot use a PDE5i, the vacuum device should be considered first-line treatment.
Written by:
Brison D, Seftel A, Sadeghi-Nejad H. Are you the author?
Urology, Facey Medical Group, Mission Hills, CA, USA.
Reference: J Sex Med. 2013 Apr;10(4):1124-35.
doi: 10.1111/jsm.12046
PubMed Abstract
PMID: 23347150
UroToday.com Erectile Dysfunction Section
